Clinical Scorecard: Liquid Biopsy Supports Precision Oncology

At a Glance

Key Highlights

• Liquid biopsy offers earlier molecular insights and faster turnaround times.
• ctDNA analysis captures tumor heterogeneity and resistance mechanisms.
• Integration into lung cancer pathways reduced time to treatment allocation significantly.
• In breast cancer, ctDNA testing identified actionable variants in 46% of patients.
• Liquid biopsy complements tissue testing, enhancing access to targeted therapies.

Guideline-Based Recommendations

Diagnosis

• Utilize liquid biopsy for patients with limited tissue availability.

Management

• Incorporate ctDNA analysis into treatment decision-making processes.

Monitoring & Follow-up

• Use liquid biopsy to monitor tumor evolution and resistance.

Risks

• Be aware of analytical challenges such as clonal hematopoiesis.

Patient & Prescribing Data

Patients with lung and breast cancer requiring genomic profiling.

Liquid biopsy can identify actionable variants earlier than tissue testing.

Clinical Best Practices

• Integrate ctDNA testing early in the diagnostic pathway.
• Ensure advanced bioinformatics are in place to interpret ctDNA results.
• Monitor ctDNA levels to assess treatment response and resistance.

References

• Illumina Webinar on Liquid Biopsy